Flerie AB (publ) Year-end report 2025
21 januari, 08:00
The period in brief
- Net asset value was SEK 3,377 million (4,198) and net asset value per sharewas SEK 43.60 (53.77 at 31 December 2024). Change in net asset value per share in the quarter was -13.8 per cent (-1.5)
- Total fair value of shares in portfolio companies was SEK 2,620 million (3,072). Change in fair value of shares in portfolio companies in the quarter was SEK -529 million (-75), equivalent to -17.1 per cent (-2.5)
- Net profit/loss amounted to SEK -541 million (-64)
- Earnings per share before and after dilution amounted to SEK -6.98 (-0.82)
- The Board of Directors proposes that no dividend be paid for the 2025 financial year
Significant events during the quarter
- Flerie divested its holdings in the investment funds that constitute the company’s Limited Partnership segment. The divestment was approved at an EGM and amounted to SEK 109 million
- On December 29 EGMs in both companies approved the merger plan between Flerie and Lipum
- Empros Pharma reported study results positioning EMP16 as an oral weight-loss maintenance therapy
- AnaCardio reported strong Phase 2a data for AC01 in patients with heart failure
- Flerie increased their ownership in Prokarium through an internal financing that reduced the reported net asset value
- Xspray Pharma's FDA approval for Dasynoc® was delayed following concerns at contract manufacturer
Flerie will host a live presentation today, Wednesday January 21, at 11:00 CET. The call will be hosted by Ted Fjällman (CEO) and Cecilia Stureborg von Schéele (CFO). The presentation will be held in English and include a Q&A session.
If you wish to participate via webcast please register via the link below. Please note that it may take a few minutes to receive the confirmation e-mail with the Teams link following registration.
https://events.teams.microsoft.com/event/42d03546-1b4a-4a9f-a0b1-540996ede963@8a6f565d-42e1-4b27-93d3-51ae5cf1e4a2
The presentation will be available after the webcast at www.flerie.com.
This information is information that Flerie AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-01-21 08:00 CET.
Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com
For more information:
Ted Fjällman, CEO
Email: ir@flerie.com
Attachments
Flerie Interim Report Q4 2025
Ämnen i artikeln
Flerie AB (publ) Year-end report 2025
21 januari, 08:00
The period in brief
- Net asset value was SEK 3,377 million (4,198) and net asset value per sharewas SEK 43.60 (53.77 at 31 December 2024). Change in net asset value per share in the quarter was -13.8 per cent (-1.5)
- Total fair value of shares in portfolio companies was SEK 2,620 million (3,072). Change in fair value of shares in portfolio companies in the quarter was SEK -529 million (-75), equivalent to -17.1 per cent (-2.5)
- Net profit/loss amounted to SEK -541 million (-64)
- Earnings per share before and after dilution amounted to SEK -6.98 (-0.82)
- The Board of Directors proposes that no dividend be paid for the 2025 financial year
Significant events during the quarter
- Flerie divested its holdings in the investment funds that constitute the company’s Limited Partnership segment. The divestment was approved at an EGM and amounted to SEK 109 million
- On December 29 EGMs in both companies approved the merger plan between Flerie and Lipum
- Empros Pharma reported study results positioning EMP16 as an oral weight-loss maintenance therapy
- AnaCardio reported strong Phase 2a data for AC01 in patients with heart failure
- Flerie increased their ownership in Prokarium through an internal financing that reduced the reported net asset value
- Xspray Pharma's FDA approval for Dasynoc® was delayed following concerns at contract manufacturer
Flerie will host a live presentation today, Wednesday January 21, at 11:00 CET. The call will be hosted by Ted Fjällman (CEO) and Cecilia Stureborg von Schéele (CFO). The presentation will be held in English and include a Q&A session.
If you wish to participate via webcast please register via the link below. Please note that it may take a few minutes to receive the confirmation e-mail with the Teams link following registration.
https://events.teams.microsoft.com/event/42d03546-1b4a-4a9f-a0b1-540996ede963@8a6f565d-42e1-4b27-93d3-51ae5cf1e4a2
The presentation will be available after the webcast at www.flerie.com.
This information is information that Flerie AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-01-21 08:00 CET.
Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com
For more information:
Ted Fjällman, CEO
Email: ir@flerie.com
Attachments
Flerie Interim Report Q4 2025
Ämnen i artikeln
Analyser
Analyser
Marknadsöversikt
1 DAG %
Senast
1 mån
